The upgrade from Market Perform to Outperform by Leerink Partners indicates a positive outlook for Amgen. The raised price target from $267 to $318 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and potentially a rise in the stock price in the short term.